COVID-19: Does It Matter if We Never Reach Herd Immunity?
“It would be great if we reached that threshold. I think it’s very questionable that we will, and I also think we don’t need to achieve true herd immunity to return to a normal lifestyle.” by Sandi Doughton, The Seattle Times / March 8, 2021 TNS
(TNS) Of all the epidemiological jargon that has spilled over into our common vocabulary during this pandemic, none has captured the popular imagination more than herd immunity.
Few of us considered ourselves part of a herd before, but the concept rooted in livestock management made it disconcertingly clear that we, too, are animals at the mercy of a microbe. Then herd immunity became a political flashpoint for those who argued it was better to let the virus rampage than impose lockdowns.
Fred Hutch announces 2021 Harold M. Weintraub Graduate Student Award recipients
Thirteen graduate students selected for prestigious honor in biological sciences Photos of award recipients Jeremy Mseitif
SEATTLE March 1, 2021 Fred Hutchinson Cancer Research Center today announced the recipients of the 2021 Harold M. Weintraub Graduate Student Award, which recognizes outstanding achievement in graduate studies in the biological sciences. The 13 award recipients were selected for the quality, originality and significance of their work, representing a diverse range of research topics.
Nominations for this prestigious annual award are solicited internationally. This year’s awardees come from across the U.S. from the University of California, Los Angeles to the University of Texas Southwestern Medical Center to Harvard University and three international recipients from the University of Basel, Switzerland, the University of St. Andrews, UK, and the
Precigen Reports Fourth Quarter and Full Year 2020 Financial Results
- Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic -
- Strengthened balance sheet with successful public offering while streamlining operations and reducing operating costs -
- Initial data readouts from PRGN-3005 and PRGN-3006 UltraCAR-T® clinical trials demonstrated encouraging expansion, persistence and clinical activity -
- A PRGN-3006 UltraCAR-T patient achieved complete remission with incomplete hematologic recovery (CRi) per ELN criteria -
- Initiated first AdenoVerse™ immunotherapy clinical trial for PRGN-2009 in HPV-associated solid tumors -
- Interim data for AG019 ActoBiotics™ in T1D indicate encouraging trends in C-peptide levels and ability to induce antigen-specific immune modulation following only one treatment cycle of oral AG019 as monotherapy or combination -
Global coronavirus cases fell by 11% in the week leading up to February 21, marking the sixth consecutive week of declining cases, the World Health Organization said Tuesday.
Coronavirus variant will likely drive a new wave of transmission come spring, some experts say kvia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kvia.com Daily Mail and Mail on Sunday newspapers.